<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">
LSX-Blog.png

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Q&A: Life sciences innovation in New Jersey

Jose Lozano, President and Chief Executive Officer at Choose New Jersey, di...

Read More

Cancer Research UK: Partnering to accelerate cance...

Key findings: Cancer Research UK’s Commercial Partnerships team brings toge...

Read More

Addex prepares PD-LID programme for 2019 Phase 3 r...

Key findings: Switzerland-based Addex Therapeutics is preparing its lead ca...

Read More

World-first accreditation to out-of-this-world app...

Key learnings: Oxford-based Oxehealth has secured medical device accreditat...

Read More

Gates Foundation funding for DelSiTech’s silica-ba...

Key learnings: DelSiTech has been awarded significant grant funding from th...

Read More

Lifestars Awards 2018 celebrate life science succe...

LSX (formerly Biotech and Money) hosted the Lifestars Awards at the Honoura...

Read More

€79m Series C pushes Galecto Biotech’s pipeline in...

Key learnings: Ysios Capital and OrbiMed led Galecto Biotech’s €79 million ...

Read More

Driving developments to defeat ageing: Q&A with Au...

In February 2019, key stakeholders in the growing longevity industry will c...

Read More

Artios Pharma’s £65m Series B to spur development ...

Key findings:

Read More

Dyadic International: Working to change the game i...

Key learnings:

Read More

What life sciences companies need to know about pr...

Pre-approval access is evolving at a rapid pace. Mark Corbett (pictured), E...

Read More

Evox Therapeutics raises £35.5m Series B to advanc...

Key learnings: UK biotech Evox Therapeutics recently announced its £35.5 mi...

Read More

Add Your Response